Skip to main content

Advertisement

Springer Nature Link
Log in

Review of Immune Therapies Targeting Ovarian Cancer

  • Gynecologic Cancers (LA Cantrell, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term “immunotherapy” envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1–2 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ovarian cancer—cancer stat facts [Internet]. [cited 2018 May 21]. Available from: https://seer.cancer.gov/statfacts/html/ovary.html

  2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  Google Scholar 

  3. Vargas-Hernández VM, Moreno-Eutimio MA, Acosta-Altamirano G, Vargas-Aguilar VM. Management of recurrent epithelial ovarian cancer. Gland Surg. 2014;3(3):198–202.

    PubMed  PubMed Central  Google Scholar 

  4. Marth C, Reimer D, Zeimet AG. Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Ann Oncol. 2017;28(suppl_8):viii36–9.

    Article  CAS  Google Scholar 

  5. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    Article  CAS  Google Scholar 

  6. National Comprehensive Cancer Network. Ovarian Cancer v 2.2018.

  7. National Institutes of Health. Surveillance, epidemiology, end results: ovarian cancer.

  8. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | NEJM [Internet]. 2011 [cited 2018 May 22]. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1103849

  9. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018 [cited 2018 May 22]; Available from: https://www.nejm.org/doi/10.1056/NEJMoa1716078?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dwww.ncbi.nlm.nih.gov

  10. Trastuzumab after adjuvant chemotherapy in HER2-Positive breast cancer | NEJM 2005 [Internet]. [cited 2018 May 22]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa052306

  11. Clarke B, Tinker AV, Lee C-H, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402.

    Article  CAS  Google Scholar 

  12. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | NEJM [Internet]. 2003 [cited 2018 May 22]. Available from: https://www.nejm.org/doi/10.1056/NEJMoa020177?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov

  13. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–43.

    Article  CAS  Google Scholar 

  14. Hwang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8.

    Article  Google Scholar 

  15. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.

    Article  CAS  Google Scholar 

  16. Mocellin S, Benna C, Pilati P. Coinhibitory molecules in cancer biology and therapy. Cytokine Growth Factor Rev. 2013;24(2):147–61.

    Article  CAS  Google Scholar 

  17. Fife BT, Bluestone JA. Control of peripheral T cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166–82.

    Article  CAS  Google Scholar 

  18. Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The Journal of Experimental Medicine. 1995. 182: 459–465. J Immunol. 2011;187(7):3459–65.

    CAS  PubMed  Google Scholar 

  19. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98–106.

    Article  CAS  Google Scholar 

  20. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  Google Scholar 

  21. Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017;44(2):136–40.

    Article  CAS  Google Scholar 

  22. •• Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity. JCO. 2016;34(15_suppl):5533 Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.5533. A preliminary analysis for trial of avelumab in patients with recurrent or refractory ovarian cancer. Responses for patients that were PD-L1+ were compared with PD-L1- expression.

    Article  Google Scholar 

  23. Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer—study results - ClinicalTrials.gov [Internet]. [cited 2018 Mar 28]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01611558. A trial to investigate the overall response and adverse events related to ipilimumab as a monotherapy for recurrent ovarian cancer.

  24. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;14:JCO2017776385.

    Google Scholar 

  25. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer | NEJM [Internet]. 2012 [cited 2018 May 25]. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1200694

  26. Niraparib in combination with pembrolizumab in patients with triple-negative breast cancer or ovarian cancer - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02657889

  27. PEMBRO with chemo in neo adj treatment of ovarian cancer - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03275506

  28. A phase II study of nivolumab/bevacizumab - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02873962

  29. A study in ovarian cancer patients evaluating rucaparib and nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03522246

  30. ATALANTE: atezolizumab vs placebo phase III study in late relapse ovarian cancer treated with chemotherapy + bevacizumab - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02891824

  31. Lee J-M, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, et al. Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1–3 inhibitor cediranib in women’s cancers: a dose-escalation, phase I study. JCO. 2017;35(19):2193–202.

    Article  CAS  Google Scholar 

  32. A Study of atezolizumab versus placebo in combination with paclitaxel, carboplatin, and bevacizumab in participants with newly-diagnosed stage iii or stage iv ovarian, fallopian tube, or primary peritoneal cancer - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT03038100

  33. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  Google Scholar 

  34. Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, et al. Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology [Internet]. 2017 Jan 6 [cited 2018 Apr 2];6(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353914/

  35. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–98.

    Article  Google Scholar 

  36. Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, et al. Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement. Clinical Cancer Research [Internet]. 2018 Jan 19 [cited 2018 Jun 6]; Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-1805

  37. Olaparib, durvalumab, and tremelimumab in treating patients with recurrent or refractory ovarian, fallopian tube or primary peritoneal cancer with BRCA1 or BRCA2 mutation - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02953457

  38. Pembrolizumab in treating participants with metastatic, recurrent or locally advanced cancer and genomic instability - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03428802

  39. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang X-Y. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–75.

    Article  CAS  Google Scholar 

  40. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, et al. Phase I trial of “bi-shRNAifurin/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol Ther. 2012;20(3):679–86 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293620/.

    Article  CAS  Google Scholar 

  41. Manning L, Barve M, Wallraven G, Kumar P, Taquet N, Bognar E, et al. Assessment of low dose Vigil® engineered autologous tumor cell (EATC) immunotherapy in patients with advanced solid tumors. Clin Oncol. 2017;2:4.

    Google Scholar 

  42. Trial of Adjuvant FANG™ vaccine for high risk stage III/IV ovarian cancer - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT01309230

  43. Phase 2 trial of maintenance vigil for high risk stage IIIb-IV ovarian cancer - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02346747

  44. Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, et al. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39’: an analysis of safety and immune response. Clin Immunol. 2018; Available from: http://www.sciencedirect.com/science/article/pii/S1521661617308653.

  45. Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients. Clin Cancer Res. 2018. A phase I study that demonstrates that generation of an immune response to folate receptor vaccination occurs in a large number of patients in clinical remission and remains detectable at 1 year.

  46. PH3 study of mirvetuximab soravtansine vs investigator’s choice of chemotherapy in women with Fra+ Adv. EOC, primary peritoneal or fallopian tube cancer - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Jun 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT02631876

  47. Altwerger G, Bonazzoli E, Bellone S. In Vitro and in vivo activity of IMGN853, an antibody–drug conjugate targeting folate receptor alpha linked to DM4, in biologically aggressive endometrial cancers. Mol Cancer Ther. 2018; Available from: http://mct.aacrjournals.org/content/17/5/1003.long.

  48. Ab O, Whiteman KR, Bartle L. IMGN853, a folate receptor-α (FRα)–targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol Cancer Ther. 2015; Available from: http://mct.aacrjournals.org/content/14/7/1605.long.

  49. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.

    Article  Google Scholar 

  50. Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii1–7 Available from: https://academic.oup.com/annonc/article/28/suppl_8/viii1/4693810.

    Article  CAS  Google Scholar 

  51. Battaglia A, Fossati M, Buzzonetti A, Scambia G, Fattorossi A. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients. Immunol Lett. 2017;191:35–9.

    Article  CAS  Google Scholar 

  52. • Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, et al. p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy. Clin Cancer Res. 2018;24(6):1315–25 Available from: http://clincancerres.aacrjournals.org.proxy-hs.researchport.umd.edu/content/24/6/1315. A phase I trial to demonstrate that response to p53 vaccination in conjunction with cytotoxic chemotherapy correlates with longer PFS.

    Article  CAS  Google Scholar 

  53. Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D, et al. Adoptive immunotherapy against ovarian cancer. J Ovarian Res. 2016;9 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869278/.

  54. Krishnan V, Berek JS, Dorigo O. Immunotherapy in ovarian cancer. Curr Probl Cancer. 2017;41(1):48–63.

    Article  Google Scholar 

  55. Uppendahl LD, Dahl CM, Miller JS, Felices M, Geller MA. Natural killer cell-based immunotherapy in gynecologic malignancy: a review. Front Immunol. 2018;8 Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2017.01825/full.

  56. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–9.

    Article  CAS  Google Scholar 

  57. Yang Y, Lim O, Kim TM, Ahn Y-O, Choi H, Chung H, et al. Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors. Cancer Immunol Res. 2016;4(3):215–24.

    Article  CAS  Google Scholar 

  58. Eguizabal C, Zenarruzabeitia O, Monge J, Santos S, Vesga MA, Maruri N, et al. Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front Immunol. 2014;5:439.

    Article  Google Scholar 

  59. Klapdor R, Wang S, Hacker U, Büning H, Morgan M, Dörk T, et al. Improved Killing of ovarian cancer stem cells by combining a novel chimeric antigen receptor-based immunotherapy and chemotherapy. Hum Gene Ther. 2017;28(10):886–96.

    Article  CAS  Google Scholar 

  60. Martín-Antonio B, Suñe G, Perez-Amill L, Castella M, Urbano-Ispizua A. Natural killer cells: angels and devils for immunotherapy. Int J Mol Sci. 2017;29:18(9).

    Google Scholar 

  61. Liu J, Li H, Cao S, Zhang X, Yu J, Qi J, et al. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother. 2014;37(2):115–22.

    Article  CAS  Google Scholar 

  62. Zhang Z, Wang L, Luo Z, Zhao X, Huang J, Li H, et al. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy. 2015;17(8):1130–8.

    Article  CAS  Google Scholar 

  63. Zhang C, Zhang Z, Wang L, Han J, Li F, Shen C, et al. Pseudomonas aeruginosa-mannose sensitive hemagglutinin injection treated cytokine-induced killer cells combined with chemotherapy in the treatment of malignancies. Int Immunopharmacol. 2017;51:57–65.

    Article  CAS  Google Scholar 

  64. Rodriguez-Garcia A, Minutolo NG, Robinson JM, Powell DJ. T cell target antigens across major gynecologic cancers. Gynecol Oncol. 2017;145(3):426–35.

    Article  CAS  Google Scholar 

  65. Andersen R, Donia M, Westergaard MCW, Pedersen M, Hansen M, Svane IM. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Hum Vaccin Immunother. 2015;11(12):2790–5.

    Article  Google Scholar 

  66. Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, et al. T-cell responses to TP53 “hotspot” mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018. In this paper, TILs from ovarian cancer patients were found to have specificity to mutated neoantigens and that these T cells could be used for adoptive cell therapy. TP53 “hotspot” reactive T cells were also found and these cells could recognize a broad range of tumor types in unrelated individuals.

  67. Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, et al. Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer. Nat Commun. 2018. 1092;9(1):15.

    Google Scholar 

  68. Pedersen M, Westergaard M, Nielsen M, Borch TH, Poulsen LG, Hendel H, et al. 1145PDAdoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic ovarian cancer: a pilot study. Ann Oncol. 2017;28(suppl_5) Available from: https://academic.oup.com/annonc/article/28/suppl_5/mdx376.010/4109224.

  69. Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, et al. Phase I trial of ALT-801, an interleukin-2/T cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011;17(24):7765–75.

    Article  CAS  Google Scholar 

  70. Zhu X, Cai H, Zhao L, Ning L, Lang J, Zhu X, et al. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017;8(38):64607–21.

    PubMed  PubMed Central  Google Scholar 

  71. Tanyi JL, Haas AR, Beatty GL, Stashwick CJ, O’Hara MH, Morgan MA, et al. Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. JCO. 2016;34(15_suppl):5511.

    Article  Google Scholar 

  72. Lanitis E, Dangaj D, Hagemann IS, Song D-G, Best A, Sandaltzopoulos R, et al. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS ONE. 2012;7(11):e49829.

    Article  CAS  Google Scholar 

  73. Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, et al. Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells. J Immunother. 2017;40(3):104–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland-Baltimore, 22 S. Greene Street S3AX31, Baltimore, MD, 21201, USA

    Cong (Ava) Fan BS, Jocelyn Reader PhD & Dana M. Roque MD

Authors
  1. Cong (Ava) Fan BS
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Jocelyn Reader PhD
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Dana M. Roque MD
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Dana M. Roque MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fan, C.(., Reader, J. & Roque, D.M. Review of Immune Therapies Targeting Ovarian Cancer. Curr. Treat. Options in Oncol. 19, 74 (2018). https://doi.org/10.1007/s11864-018-0584-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-018-0584-3

Keywords